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Abstract Present cancer treatment strategies are based on
the assumption that a therapy may work (“response”) or not
work (“no-response”). However, the existing evidence
suggests that current cancer treatment modalities may also
have a cancer-promoting effect in part of the patients. In
this paper, some relevant data are reviewed suggesting that
surgery, irradiation, chemotherapy and immunotherapy can
stimulate tumor growth / metastatic spread and decrease
survival of patients in certain subgroups. Thus, results of
cancer treatment may be improved by detection and use of
biomarkers that correlate with positive or negative thera-
peutic effects. Small trials based on groups with differing
biomarkers rather than large phase III trials may aid the
development and efficacy testing of new anticancer drugs.
Moreover, ignoring biomarkers that correlate with positive
or negative therapeutic effect may not be compatible
anymore with the ethical principle “First Do No Harm”.
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Introduction
“…when trials were first developed for use in
agriculture, researchers were presumably concerned
about the effect of interventions on the overall size
and quality of the crop rather than on the wellbeing of
any individual plant.”
P. M. Rothwell, 2005 [1]
Survival of patients with some forms of cancer (e.g.,
testicular cancer, Hodgkin’s disease, acute childhood
leukemia) has improved dramatically during the last
decades due to advances in chemotherapeutic regimens as
well as surgical and radiotherapeutic techniques. The price
of cure or long term survival are acute toxic effects (e.g.
radiation pneumonitis, acute renal failure, sepsis), chronic
toxic effects (e.g. pulmonary fibrosis, congestive heart
failure, graft versus host disease, neurological syndromes,
infertility, hypothyroidism) and second malignancies [2].
As cancer treatments have become more effective, it has
even been suggested to tailor therapies based on late
toxicities rather than survival [3]. A question that has
received far less attention is whether present cancer
treatment modalities may actually have a cancer-
promoting effect. The aim of the present review is to
provide the evidence, suggesting that surgery, irradiation,
chemotherapy and immunotherapy may stimulate tumor
growth and / or metastatic spread and by these or other
mechanisms decrease the survival of certain patient
subgroups.
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Cancer-promoting effects of surgery
Presently, surgery is the most effective primary modality of
therapy against cancer and possible detrimental effects of
primary tumor removal are rarely discussed. Nevertheless,
most cancer surgeons have observed rapid tumor regrowth
shortly after primary surgery [4, 5].
Some experimental evidence has indicated that removal of
a primary tumor (and / or surgical stress) may enhance the
growth of residual tumor and the development of metastases
[5–9]. Appearance of growth-stimulating factor in serum
after primary tumor removal [9], abrogation of immune or
nonimmunologic growth inhibiting factors [8], increased
angiogenesis [5] and surgical stress induced immunosup-
pression [10] have been implicated as possible mechanisms
for this phenomenon. It has been show in an experimental
mouse model, that presence of the primary tumor influences
antitumor mechanisms against the secondary tumor, al-
though the nature of these mechanisms is not completely
understood [11]. Thus, the presence of a primary tumor
might have a protective effect against metastases.
For obvious ethical reasons, comparative clinical trials to
evaluate the influence of primary tumor surgery on metastatic
spread have not been performed. Evidence that surgery
provokes activation of “latent” metastases in early breast
cancer was presented by Michael Retsky and his colleagues
[12]. This evidence was generated by interpretation of the
results of natural history databases and clinical trials using
hazard rate plots. A patient presenting with a primary breast
tumor along with distant metastases is uncommon (0%, 3%
and 7% in stages I, II and III, respectively). However,
18 months after diagnosis and therapy distant metastases are
detected in 5% stage I and in 25% stage III breast cancer
patients. The explanation of this fact could be that the clinical
appearance of metastases is triggered or accelerated after the
primary tumor has been removed [13]. Mean survival of
patients with locally advanced or metastatic breast cancer is
approximately two and a half years. However, 18% of
untreated patients even with locally advanced or overt
metastatic disease survived 5 years and 0.8% patients
survived 15 years. A small group of breast cancer patients
with untreated localized disease could be identified with near
70% 5-year survival. On the other hand, only 23% of patients
treated with radical mastectomy survive 10 years [13].
Cancer-promoting effects of radiotherapy
Radiation therapy has been in use as a cancer treatment for
more than a century, with its earliest roots traced from the
discovery of x-rays in 1895 by Wilhelm Röntgen. Two-thirds
of all cancer patients will be treated with radiotherapy at some
point in their life [14]. Ionizing radiation causes DNA
damage through induction of breaks in one or both of
DNA strands. Since cancer cells display deregulated cell
cycle control and increased proliferation they are more
vulnerable to irradiation than normal cells which usually are
able to repair the DNA damage or to induce cell death in
those cells in which DNA damage cannot be repaired.
The effect of radiation on cancer cell or normal cell does not
always take place immediately after treatment. Some of the
cells will stay unchanged for weeks or months after treatment.
This is due to the fact that radiation damaged cells can stay alive
as long as all DNA is present. However, proper cell division is
impossible after DNA is damaged. These radiation damaged
cells can initiate a second cancer somewhere else in the body.
Numerous studies confirmed that radiotherapy increases
the risk of second malignancies. Radiation-induced bone
cancers and soft tissue sarcomas have been observed in long-
term survivors of hereditary retinoblastoma.Most deaths from
these secondary malignancies occurred within 30 years after
retinoblastoma diagnosis [15]. In patients with Hodgkin’s
lymphoma, causes other than primary disease contribute
most to excess mortality 10 years after radiotherapy. Solid
tumors, especially from the digestive and respiratory tract,
contribute most to this excess mortality, followed by
cardiovascular disease [16]. Statistically significantly in-
creased risks of solid cancers (lung, colon, bladder, pancreas,
pleura and esophagus) are observed among long-term
survivors of testicular cancer treated with radiotherapy alone
[17]. Men who receive radiotherapy for localized prostate
cancer have an increased risk of bladder cancer compared to
patients undergoing radical prostatectomy and compared to
the general population. The risk of rectal cancer is increased
in patients who receive external beam radiotherapy com-
pared to radical prostatectomy [18].
The incidence of second malignancies caused by
radiotherapy is relatively low. Second solid malignancies
are rarely seen before 10 years, with increasing incidence
thereafter. From this point of view, benefits of radiotherapy
clearly outweigh its potential harm and the widespread use
of this form of cancer treatment seems justified [19]. On the
other hand, radiotherapy-induced second cancers illustrate
the cancer-promoting effect of this treatment modality.
Similarly to surgical eradication of a primary tumor,
radiation therapy may also induce the explosive growth of
previously dormant metastases in experimental models [20,
21]. This phenomenon has been explained by the decrease
of the angiostatin production which is regulated by the
primary tumor [21].
Cancer-promoting effects of chemotherapy
Chemotherapy has provided curative treatments for some
forms of cancer (acute childhood leukemia, testicular
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cancer, and Hodgkin’s disease) that were previously fatal.
However, the role of chemotherapy in other more common
cancers is quite modest, with survival improvement
measuring few months or only few weeks [22].
One of the ironies of chemotherapeutic successes has
been the recognition that many cytotoxic drugs are
themselves carcinogenic. It is worth mentioning, that death
receptors, once thought to primarily induce cytotoxic
signaling cascades, recently have been shown to initiate
multiple signaling pathways, including regulation of cell
proliferation and tumor-promoting activities [23]. The
carcinogenic risk is especially great with alkylating agents
and the epipodophyllotoxins, but carcinogenicity has also
been described for antimetabolites, anthracyclines, cisplatin
and others. Most often, these chemotherapeutic agents
cause the development of acute myeloid leukemia, high-
grade non-Hodgkin’s lymphoma, and myelodysplastic
syndrome. The risk of secondary leukemia peaks at around
5 years after treatment [24].
It has been observed that if patients receive suboptimal
doses of chemotherapeutic drugs, they are not cured, and
their survival is shorter compared to patients who receive
optimal doses (although is not always clear what doses
should be considered “optimal”) [25, 26]. Even with
optimal doses, chemotherapy is not likely to be effective
for all patients. A number of molecular markers have been
identified that have predictive value for the outcome of
treatment with chemotherapeutic drugs of non-small cell
lung cancer [27], pancreas [28], breast [29], colorectal
cancer [30], diffuse large B-cell lymphoma [31] and other
cancers. The efficacy and toxicity of current chemothera-
peutic regimens may depend on genetic factors, like
cytochrome P450 polymorphisms [32]. It has been shown
that the risk of breast cancer mortality is increased in
tamoxifen users with decreased CYP2D6 activity [33].
Chemotherapy is infamous for its side effects, encom-
passing virtually every system in the body [24]. Some of
these side effects, like cardiotoxicity, are potentially lethal
[34]. Thus, in some patients for whom chemotherapy is not
curative, detrimental or even lethal effects of chemothera-
peutic agents are likely to outweigh modest antitumor effect
and thereby decrease survival of a patient. Our unpublished
observations in a rat model have shown that docetaxel
treatment of multidrug resistant prostate cancer decreases
survival time of animals [JJLJ et al., manuscript in
preparation]. Furthermore, patients undergoing antineoplas-
tic treatment experience various changes in the immune
system, which not only render them susceptible to
infections, but also might have an overall effect on the risk
of relapse [35].
The generally held view is than a placebo group in
cancer clinical trials is unethical. Therefore, a cancer
promoting-effect of chemotherapy may remain obscured.
Experimental animal research, however, has shown that
chemotherapy can even stimulate the metastatic spread of
the primary tumor [36, 37].
Cancer-promoting effects of immunotherapy
In the past few decades, immunotherapy has become the
fourth cancer treatment modality. Presently, intravesical
immunotherapy with Bacillus Calmette-Guérin (BCG) is
regarded as the most effective protection against recur-
rence and progression in high-risk bladder cancer patients
[38]. Recombinant cytokines (interferon-α and
interleukin-2) demonstrate reproducible activity in some
forms of cancer, including renal cell carcinoma and
melanoma. Despite complete or partial response rate with
cytokines is rather low, some patients achieve long-lasting
remissions [39–41]. Monoclonal antibodies, vaccination
therapy and adoptive cell transfer are rapidly evolving
fields of cancer immunotherapy.
The “immunostimulatory theory” of tumor growth was
proposed by Prehn in the 1970s [42]. Several investigators
have demonstrated in experimental models that immuno-
therapy against established tumors or against residual tumor
cells can produce not only inhibitory or null effects, but
also can stimulate tumor growth and spread of metastases
[43–47].
Probably the first immunotherapy for which detrimental
effects were observed was interferon-γ. Adjuvant treatment
with this cytokine decreased overall survival and/or
disease-free survival compared with observation arm
(although not always statistically significantly) in high-
risk melanoma [48], colon cancer [49] and small-cell lung
cancer patients [50].
Interferon-α (IFN-α) has produced only modest benefits
in unselected advanced renal carcinoma patients. Meta-
analysis of 42 randomized, controlled trials of IFN-α,
including 4,216 patients, revealed the overall survival
advantage of 3.8 months for IFN-α treated patients [41].
Despite this benefit of IFN-α was quite modest, for
considerable period of time IFN-α was the de facto
standard of care of metastatic renal cell carcinoma
worldwide. Regulatory agencies have supported the use of
IFN-α as the control arm for randomized trials with new
therapies [41]. Therefore, it was impossible to perform a
study including a control group of untreated renal cell
carcinoma patients. Obviously, a control group of untreated
patients is necessary to determine the biomarkers of
response or non-response.
In the late nineties, our group has studied the prognostic
and predictive significance of immunologic markers in
peripheral blood of renal cell carcinoma patients. During
1995–1999, IFN-α was just being introduced in Lithuania,
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and no strict guidelines towards its use for treatment of
metastatic renal cell carcinoma were available. Due to
considerable variability in approach to treatment of meta-
static renal cell carcinoma patients in Lithuania, we were
able to select subgroups of patients treated and non-treated
with IFN-α. Peripheral blood lymphocyte subsets were
determined using flow cytometry. Thus, we had the
opportunity to analyze the predictive significance of
peripheral blood lymphocyte subsets in patients with
advanced renal cell carcinoma. We found remarkable
differences in overall survival of advanced renal cell
carcinoma patients based on peripheral blood levels of
CD8highCD57+ lymphocytes [51]. In our analysis, the
median survival of patients with <30% CD8highCD57+
lymphocytes in the CD8+ subset was 23.5 months (the
“relatively good prognosis group”), whereas the median
survival of patients with ≥ 30% CD8highCD57+ lympho-
cytes in the CD8+ subset was only 6 months (the “bad
prognosis group”). Treatment with IFN-α significantly
increased the overall survival of the “bad prognosis group”
renal cell carcinoma patients (from 6 to 18.5 months). In
contrast, a trend towards decreased overall survival was
observed in the “relatively good prognosis group” after
treatment with IFN-α (13.6 months of IFN-α-treated
patients vs. 23.5 months of patients non-treated with IFN-
α) (Fig. 1) [51]. Although we admit the drawbacks of our
study due to its retrospective nature, the remarkable
differences in patient survival related to counts of
CD8highCD57+ lymphocytes cannot be ignored. The
utility of CD57+ expression in T lymphocytes to measure
functional immune deficiency in patients with autoimmune
disease, infectious diseases, and cancers has recently been
reviewed [52].
Similarly to IFN-α therapy of renal cell carcinoma,
adjuvant therapy with IFN-α of high-risk melanoma is only
minimally effective in a nonselected patient population
[53]. In a recent systematic review and meta-analysis of 14
randomized controlled trials including a total of 8,122
patients, statistically significant improvement in overall
survival of high-risk melanoma patients treated with IFN-α
vs. comparator regimen or observation was shown [54].
However, the authors of this systematic review and meta-
analysis admit that this improvement cannot be considered
satisfying in terms of anticancer efficacy.
Several reports have suggested the involvement of CD8+
CD57+ T lymphocytes in control of melanoma progression
[55–57]. In our study of melanoma patients treated with
adjuvant IFN-α, we observed remarkable differences in
survival depending on pre-treatment levels of
CD8highCD57+ lymphocytes in peripheral blood. Median
survival time of patients with >23% CD8highCD57+
lymphocytes in CD8+ subset was 14.2 months, whereas
median survival time of patients with <23% CD8highCD57+
lymphocytes was not reached at the time of analysis (median
follow-up 24.6 months). The cut-off level of 23% in the
present study was found by separating patients with increas-
ing values of CD8highCD57+ lymphocytes during the first
few months of treatment with IFN-α from those with
decreasing values. This means that lower (<23%) pre-
treatment values of these lymphocytes tend to increase,
whereas higher values (>23%) tend to decrease during
therapy. Thus, IFN-α seems to induce opposite changes in
peripheral blood CD8highCD57+ lymphocyte levels (i.e.
increase or decrease) depending on their pre-treatment values
[58]. The opposite action of adjuvant IFN-α on immune
parameters in different subgroups of patients may explain the
null or minimal effect of this treatment on the whole
population of unselected melanoma patients.
Probably the most recent examples of detrimental effects
of cancer immunotherapy include the failure of several
vaccine trials. The survival of stage III and stage IV
melanoma patients receiving the allogeneic cancer vaccine
Canvaxin™ was shorter compared with untreated patients.
The large phase III EORTC 18961 trial of adjuvant
ganglioside vaccine GMK in 1,314 patients with stage II
melanoma was stopped earlier because of inferior survival
in the vaccine arm [59].
Conclusions and future perspectives
In this paper, the data have been reviewed suggesting that
current cancer treatment modalities may also have a cancer-
promoting effect (Fig. 2). These data do not mean that
current cancer therapies are not beneficial. In some cases,
like radiotherapy of localized cancer, benefits of treatment
≥30% CD8hCD57+
5
10
15
20
25
Non-treated
Treated
M
ed
ia
n 
su
rv
iva
l (m
on
ths
)
<30% CD8hCD57+
Fig. 1 Median survival times of advanced renal cell carcinoma
patients according to treatment with IFN-α and percentage of
CD8highCD57+ lymphocytes in CD8+ subset (in peripheral blood)
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clearly outweigh the risk of second cancers developing after
long latent period. In other cases, like cytokine therapy of
renal cell carcinoma or melanoma the benefit / risk ratio
seems much more uncertain. A cancer promoting-effect of
many therapies may remain obscured due to the generally
held view that an untreated group in cancer clinical trials is
unethical.
The evidence reviewed in this paper challenges the
assumption that in cancer patients who do not respond to
therapy, the course of disease is the same as without
treatment. The existing data highlight the possibility of the
qualitative heterogeneity of relative treatment effect, de-
fined as the treatment effect being in different directions in
different groups of patients [1]. Thus, a subgroup of
patients may have beneficial effects from a therapy,
whereas another subgroup may have detrimental effects.
This possibility has major implications for cancer clinical
practice and for testing efficacy of new drugs.
The results of cancer treatment may be improved by
using biomarkers that correlate with positive or negative
therapeutic effect. Great numbers of biomarkers have
been detected, but few of them are used in clinical
practice. The suspicion that a given therapy has a
cancer-promoting effect in a subgroup of patients might
provide an urgent stimulus to introduce and to use the
predictive biomarkers. Therefore, the most relevant for
implementation biomarkers should be selected and
applied in clinical practice.
Large clinical trials always may contain subgroups in
which beneficial or detrimental effects are obtained. As
a result, the total effect of the therapeutic intervention
would be nullified. This would be a strong argument
against large clinical phase III trials. Thus, small
comparative trials based on groups of patients with
different predictive biomarkers may be preferable for
testing efficacy of new drugs [22, 60]. Another argument
in favor of small comparative trials based on predictive
biomarkers is that a lower number of patients would suffer
a detrimental effect of an investigative therapy, if such a
detrimental effect would exist. Given the possibility of a
cancer-promoting effect of an anticancer intervention,
a group of untreated patients might be acceptable from
the ethical point of view.
In conclusion, the probability of a cancer-promoting
effect of current cancer treatment modalities emphasizes
the importance of prediction and personalized approach
in oncology. Ignoring biomarkers that correlate with
positive or negative therapeutic effect may not be
compatible anymore with the ethical principle “First
Do No Harm”.
Fig. 2 Summary of data indicating cancer-promoting effects of surgery, radiotherapy, chemotherapy and immunotherapy
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